vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and CLEANSPARK, INC. (CLSK). Click either name above to swap in a different company.
Axsome Therapeutics, Inc. is the larger business by last-quarter revenue ($191.2M vs $181.2M, roughly 1.1× CLEANSPARK, INC.). On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (57.4% vs 11.6%). Over the past eight quarters, CLEANSPARK, INC.'s revenue compounded faster (106.4% CAGR vs 48.1%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
CleanSpark, Inc. is a U.S.-headquartered sustainable technology company operating two core business segments: low-carbon Bitcoin mining powered primarily by renewable and stranded energy resources, and end-to-end microgrid design, deployment, and operation services for commercial, industrial, and public sector clients across North America.
AXSM vs CLSK — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $191.2M | $181.2M |
| Net Profit | — | $-378.7M |
| Gross Margin | — | 47.2% |
| Operating Margin | -33.1% | -174.7% |
| Net Margin | — | -209.0% |
| Revenue YoY | 57.4% | 11.6% |
| Net Profit YoY | — | -253.5% |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $191.2M | — | ||
| Q4 25 | $196.0M | $181.2M | ||
| Q3 25 | $171.0M | — | ||
| Q2 25 | $150.0M | — | ||
| Q1 25 | $121.5M | — | ||
| Q4 24 | $118.8M | — | ||
| Q3 24 | $104.8M | $89.3M | ||
| Q2 24 | $87.2M | $104.1M |
| Q1 26 | — | — | ||
| Q4 25 | $-28.6M | $-378.7M | ||
| Q3 25 | $-47.2M | — | ||
| Q2 25 | $-48.0M | — | ||
| Q1 25 | $-59.4M | — | ||
| Q4 24 | $-74.9M | — | ||
| Q3 24 | $-64.6M | $-62.2M | ||
| Q2 24 | $-79.3M | $-236.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | 47.2% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 36.0% | ||
| Q2 24 | — | 56.6% |
| Q1 26 | -33.1% | — | ||
| Q4 25 | -13.8% | -174.7% | ||
| Q3 25 | -27.0% | — | ||
| Q2 25 | -24.5% | — | ||
| Q1 25 | -46.9% | — | ||
| Q4 24 | -61.1% | — | ||
| Q3 24 | -59.8% | -73.5% | ||
| Q2 24 | -89.5% | -239.2% |
| Q1 26 | — | — | ||
| Q4 25 | -14.6% | -209.0% | ||
| Q3 25 | -27.6% | — | ||
| Q2 25 | -32.0% | — | ||
| Q1 25 | -48.9% | — | ||
| Q4 24 | -63.1% | — | ||
| Q3 24 | -61.7% | -69.6% | ||
| Q2 24 | -91.0% | -226.9% |
| Q1 26 | — | — | ||
| Q4 25 | $-0.55 | — | ||
| Q3 25 | $-0.94 | — | ||
| Q2 25 | $-0.97 | — | ||
| Q1 25 | $-1.22 | — | ||
| Q4 24 | $-1.54 | — | ||
| Q3 24 | $-1.34 | — | ||
| Q2 24 | $-1.67 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $305.1M | $458.1M |
| Total DebtLower is stronger | $70.0M | $1.8B |
| Stockholders' EquityBook value | — | $1.4B |
| Total Assets | $713.6M | $3.3B |
| Debt / EquityLower = less leverage | — | 1.29× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $305.1M | — | ||
| Q4 25 | $322.9M | $458.1M | ||
| Q3 25 | $325.3M | — | ||
| Q2 25 | $303.0M | — | ||
| Q1 25 | $300.9M | — | ||
| Q4 24 | $315.4M | — | ||
| Q3 24 | $327.3M | $121.2M | ||
| Q2 24 | $315.7M | $126.1M |
| Q1 26 | $70.0M | — | ||
| Q4 25 | — | $1.8B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $7.2M | ||
| Q2 24 | — | $1.3M |
| Q1 26 | — | — | ||
| Q4 25 | $88.3M | $1.4B | ||
| Q3 25 | $73.7M | — | ||
| Q2 25 | $73.1M | — | ||
| Q1 25 | $53.2M | — | ||
| Q4 24 | $57.0M | — | ||
| Q3 24 | $92.9M | $1.8B | ||
| Q2 24 | $102.9M | $1.4B |
| Q1 26 | $713.6M | — | ||
| Q4 25 | $689.8M | $3.3B | ||
| Q3 25 | $669.3M | — | ||
| Q2 25 | $639.8M | — | ||
| Q1 25 | $596.7M | — | ||
| Q4 24 | $568.5M | — | ||
| Q3 24 | $561.5M | $2.0B | ||
| Q2 24 | $548.2M | $1.5B |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.29× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | 0.00× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-161.1M |
| Free Cash FlowOCF − Capex | — | $-198.1M |
| FCF MarginFCF / Revenue | — | -109.3% |
| Capex IntensityCapex / Revenue | — | 20.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-626.9M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $-161.1M | ||
| Q3 25 | $1.0M | — | ||
| Q2 25 | $-32.4M | — | ||
| Q1 25 | $-43.4M | — | ||
| Q4 24 | $-26.2M | — | ||
| Q3 24 | $-18.6M | $-233.7M | ||
| Q2 24 | $-30.1M | $-58.4M |
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $-198.1M | ||
| Q3 25 | $988.0K | — | ||
| Q2 25 | $-32.4M | — | ||
| Q1 25 | $-43.7M | — | ||
| Q4 24 | $-26.2M | — | ||
| Q3 24 | $-18.7M | $-299.8M | ||
| Q2 24 | $-30.2M | $-68.7M |
| Q1 26 | — | — | ||
| Q4 25 | -9.6% | -109.3% | ||
| Q3 25 | 0.6% | — | ||
| Q2 25 | -21.6% | — | ||
| Q1 25 | -36.0% | — | ||
| Q4 24 | -22.1% | — | ||
| Q3 24 | -17.9% | -335.8% | ||
| Q2 24 | -34.6% | -66.0% |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 20.4% | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.3% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.1% | 74.0% | ||
| Q2 24 | 0.1% | 9.9% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
| Product sales, net | $189.4M | 99% |
| Royalty revenue and milestone revenue | $1.8M | 1% |
CLSK
Segment breakdown not available.
